Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Vivimed Labs Ltd
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 56 | 37 | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 |
| Expenses + | 61 | 201 | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 |
| Operating Profit | -5 | -164 | -0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | -0 | -1 | -11 |
| OPM % | -9% | -444% | -1% | -18% | 3% | -74% | -37% | -3% | 3% | -10% | -1% | -5% | -68% |
| Other Income + | 0 | 1 | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Interest | 9 | 9 | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 |
| Depreciation | 4 | 96 | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 |
| Profit before tax | -18 | -268 | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 |
| Tax % | 0% | -1% | 0% | 0% | -3% | 21% | 0% | 0% | 0% | 2% | 0% | 0% | 0% |
| Net Profit + | -18 | -266 | -16 | -20 | -16 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 |
| EPS in Rs | -2.21 | -32.08 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2.00 |
Financials of Vivimed Labs Ltd
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,351 | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 84 |
| Expenses + | 1,139 | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 182 | 129 | 98 |
| Operating Profit | 212 | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -15 |
| OPM % | 16% | 16% | 17% | 28% | 18% | 14% | 1% | 4% | -3% | -100% | -22% | -11% | -18% |
| Other Income + | 8 | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 5 |
| Interest | 67 | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 5 |
| Depreciation | 66 | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 20 |
| Profit before tax | 87 | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -35 |
| Tax % | 24% | 7% | 16% | 25% | 11% | 13% | -0% | 3% | 4% | -1% | -1% | 0% | |
| Net Profit + | 66 | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -35 |
| EPS in Rs | 8.20 | 8.90 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -4.22 |
| Dividend Payout % | 7% | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Vivimed Labs Ltd
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 480 | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -65 |
| Borrowings + | 958 | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 384 |
| Other Liabilities + | 404 | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 588 |
| Total Liabilities | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 924 |
| Fixed Assets + | 808 | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 393 |
| CWIP | 38 | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 21 |
| Investments | 0 | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 168 |
| Other Assets + | 1,011 | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 342 |
| Total Assets | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 924 |
Financials of Vivimed Labs Ltd
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -118 | 140 | 154 | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 |
| Cash from Investing Activity + | -291 | -107 | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 |
| Cash from Financing Activity + | 419 | -42 | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 |
| Net Cash Flow | 11 | -8 | 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 |
| Free Cash Flow | -277 | 16 | 95 | -11 | -142 | 333 | -33 | 1,084 | 11 | 30 | -26 | -6 |
| CFO/OP | -55% | 63% | 66% | 23% | 30% | 243% | 972% | 1,720% | -352% | -19% | 73% | 13% |
Financials of Vivimed Labs Ltd
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94 | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 |
| Inventory Days | 249 | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 |
| Days Payable | 106 | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 |
| Cash Conversion Cycle | 237 | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 |
| Working Capital Days | 57 | 43 | 58 | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 |
| ROCE % | 12% | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% | -11% | -8% |